TY - JOUR T1 - Predictive Model of Risk Factors of High Flow Nasal Cannula Using Machine Learning in COVID-19 JF - medRxiv DO - 10.1101/2022.03.02.22271673 SP - 2022.03.02.22271673 AU - Nobuaki Matsunaga AU - Keisuke Kamata AU - Yusuke Asai AU - Shinya Tsuzuki AU - Yasuaki Sakamoto AU - Shinpei Ijichi AU - Takayuki Akiyama AU - Jiefu Yu AU - Gen Yamada AU - Mari Terada AU - Setsuko Suzuki AU - Kumiko Suzuki AU - Sho Saito AU - Kayoko Hayakawa AU - Norio Ohmagari Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/03/04/2022.03.02.22271673.abstract N2 - Background With the rapid increase in the number of COVID-19 patients in Japan, the number of patients receiving oxygen at home has also increased rapidly, and some of these patients have died. An efficient approach to identify high-risk patients with slowly progressing and rapidly worsening COVID-19, and to avoid missing the timing of therapeutic intervention will improve patient prognosis and prevent medical complications.Methods Patients admitted to medical institutions in Japan from November 14, 2020 to April 11, 2021 and registered in the COVID-19 Registry Japan were included. Risk factors for patients with High Flow Nasal Cannula invasive respiratory management or higher were comprehensively explored using machine learning. Age-specific cohorts were created, and severity prediction was performed for the patient surge period and normal times, respectively.Results We were able to obtain a model that was able to predict severe disease with a sensitivity of 57% when the specificity was set at 90% for those aged 40-59 years, and with a specificity of 50% and 43% when the sensitivity was set at 90% for those aged 60-79 years and 80 years and older, respectively. We were able to identify lactate dehydrogenase level (LDH) as an important factor in predicting the severity of illness in all age groups.Discussion Using machine learning, we were able to identify risk factors with high accuracy, and predict the severity of the disease. Using machine learning, we were able to identify risk factors with high accuracy, and predict the severity of the disease. We plan to develop a tool that will be useful in determining the indications for hospitalisation for patients undergoing home care and early hospitalisation.Competing Interest StatementI have read the journal's policy and the authors of this manuscript have the following competing interests: KK, YS, and SI are staff of DataRobot Inc. Other authors have no competing interests.Funding StatementThe funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The National Center for Global Health and Medicine (NCGM) ethics review board gave ethical approval for this work (NCGM-G-004133-00).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are not publicly available due to the regulation of COVIREGI-JP. A portion of the data would be available upon reasonable request to the corresponding author. ER -